Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort

Autor: Luciano Wannesson, Wolfram Jochum, H. Bouchaab, David König, Wolf-Dieter Janthur, Patrizia Frösch, Martin Früh, Alex Friedlaender, Sacha I. Rothschild, Laetitia A. Mauti, Alfredo Addeo, Izadora Demmer, Sämi Schär, Sabine Schmid, Christian Britschgi, Veronika Blum
Rok vydání: 2020
Předmět:
Zdroj: Cancer Immunology, Immunotherapy. 69:1605-1613
ISSN: 1432-0851
0340-7004
Popis: Early clinical trials showed promising outcomes with immune-checkpoint inhibitors (ICI) in a subset of patients with relapsed small-cell lung carcinoma (SCLC). The aim of this retrospective analysis was to assess the efficacy and safety of ICI for relapsed SCLC in a real-world patient population. Nine cancer centres in Switzerland contributed data to this cohort. Responses were assessed by the local investigators using standard RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were analysed by the Kaplan–Meier method. Associations between potential predictive markers and survival endpoints were probed by Cox proportional hazards. Forty-five patients were included in the analysis. Median age was 63 years, 73% were males and 18% had an ECOG performance status (PS) ≥ 2. ICIs were given as second-line treatment in 60%. Twenty-four patients (53%) received ipilimumab with nivolumab. Twenty-eight patients (62%) had undergone irradiation (RT) prior to or during ICI. Overall response rate (ORR) was 29% and median PFS and OS were 2.3 and 6.5 months, respectively. Median duration of response was 9 months (95% CI 2.8–NA). Five patients maintained their response for > 6 months, all of them receiving combination treatment. There were no new safety signals. This is the first report of “real-world” data on ICI in relapsed SCLC also including patients with poor PS. Promising durable responses were observed. No biological prognostic marker could be identified.
Databáze: OpenAIRE
Externí odkaz: